| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-02-04 | FDA (USA), NIH (USA), AbbVie (USA - IL), Biogen Idec (USA - MA), BMS (USA - NY), GSK (UK), Johnson & Johnson (USA - NJ), Lilly (USA - IN), Merck&Co (USA - NJ), Pfizer (USA - NY), Sanofi (France), Takeda (Japan), American Diabetes Association (USA), Foundation for the NIH (USA), Geoffrey Beene Foundation (USA), Lupus Foundation of America (USA), PhRMA (USA), Rheumatology Research Foundation (USA), USAgainstAlzheimer’s (USA) | Alzheimer’s disease, type 2 diabetes, rheumatoid arthritis, systemic lupus erythematosus | collaboration |
Autoimmune diseases - Neurodegenerative diseases - Metabolic diseases | R&D agreement | |
| 2014-02-04 | Cellectis (France) Genoway (France) | homologous recombination technology for research applications | licensing |
Technology - Services | Licensing agreement | |
| 2014-02-03 | Ferrer (Spain) Ildong Pharmaceuticals (South Korea) | lorediplon | insomnia | development |
CNS diseases | Development agreement |
| 2014-02-03 | Ferrer (Spain) Ergomed Clinical Research (UK) | lorediplon | insomnia | development | ||
| 2014-02-03 | Portola Pharmaceuticals (USA) Bayer (Germany) Janssen Pharmaceuticals - J&J (USA) | andexanet alfa | R&D |
Cardiovascular diseases | Clinical research agreement | |
| 2014-02-02 | MDxHealth (Belgium) Prime Health Services (USA) | ConfirmMDx for Prostate Cancer | prostate cancer | commercialisation |
Diagnostic - Cancer - Oncology | Commercialisation agreement |
| 2014-01-31 | VIB (Belgium) CD3 - KU Leuven (Belgium) AstraZeneca (UK) | MALT1 inhibitors | licensing |
Cancer - Oncology - Inflammatory diseases | Licensing agreement | |
| 2014-01-30 | Horizon Discovery (UK) undisclosed Japanese medical university (Japan) | X-MAN™ cell lines | licensing |
Technology - Services | Licensing agreement | |
| 2014-01-30 | UCB (Belgium) Biogen (USA - MA) | Biogen's portfolio of multiple sclerosis therapies and investigational candidates, including Tecdifera®, Fampyra®, Avonex®, Tysabri®, Plegridy™, Daclizumab High-Yield Process (DAC HYP), Eloctate™ and Alprolix™ | multiple sclerosis, hemophilia | commercialisation |
Neurodegenerative diseases - Rare diseases - Hematological diseases | Commercialisation agreement |
| 2014-01-29 | Kiadis Pharma (The Netherlands) Technische Universität München (Germany) | ATIR™ | collaboration |
Cancer - Oncology - Rare diseases | Collaboration agreement | |
| 2014-01-28 | Curie-Cancer (France) Servier (France) | ‘triple negative’ breast cancers | R&D |
Cancer - Oncology | R&D agreement | |
| 2014-01-28 | Eureka Therapeutics (USA) Memorial Sloan-Kettering Cancer Center (USA) Novartis (Switzerland) | monoclonal antibody ESK1 | leukemia and other cancers | development |
Cancer - Oncology | Development agreement |
| 2014-01-27 | AstraZeneca (UK) FOB Synthesis (USA) | antibiotics combining beta lactamase inhibitor and carbapenem (FSI-1671 and FSI-1686) | R&D |
Infectious diseases | R&D agreement | |
| 2014-01-27 | Sirona Biochem (Canada - France) Wanbang Biopharmaceuticals (China) | anti-diabetic SGLT2 inhibitor | diabetes | licensing |
Metabolic diseases | Licensing agreement |
| 2014-01-24 | Sanofi (France) MAbImprove (France) | aerosol antibody formulation | idiopathic pulmonary fibrosis | R&D |
Rare diseases | R&D agreement |
| 2014-01-23 | MDxHealth (Belgium) Teva Pharmaceuticals (Israel) | ConfirmMDx®, PredictMDx® | prostate cancer, glioblastoma | commercialisation |
Diagnostic - Cancer - Oncology | Commercialisation agreement |
| 2014-01-22 | Nuevolution (Denmark) The Institute of Cancer Research (ICR) (UK) Cancer Research Technology (CRT) (UK) | screening technology Chemetics® | R&D |
Cancer - Oncology | R&D agreement | |
| 2014-01-21 | Avaxia Biologics (USA - MA) Delphi Genetics (Belgium) | AVX-470 | ulcerative colitis | development production manufacturing |
Autoimmune diseases - Inflammatory diseases - Digestive diseases | Production agreement |
| 2014-01-20 | Zealand Pharma (Denmark) Boehringer Ingelheim (Germany) | ZP2929 and other dual-acting glucagon and GLP-1 receptor agonists | type 2 diabetes obesity | collaboration |
Metabolic diseases | Development agreement |
| 2014-01-20 | Cisbio Bioassays (France) Reaction Biology (USA) | epigenetic proteins | distribution |
Technology - Services | Distribution agreement |
